Table III.
Patient demographics, cancer characteristics, and cancer treatment of non-Hispanic white patients with melanoma diagnosed as less than 1-mm-thick ulcerated tumors by survival before or after 26 months
| Characterktic | Survival ≤26 mo |
Survival >26 mo |
|||
|---|---|---|---|---|---|
| 112 |
554 |
||||
| n | % | n | % | P value | |
| Sex | |||||
| Male | 78 | 69.6% | 341 | 61.6% | |
| Female | 34 | 30.4% | 213 | 38.4% | .1059 |
| Age at diagnosis, y | |||||
| <35 | 1 | 0.9% | 34 | 6.1% | |
| 35–44 | 4 | 3.6% | 41 | 7.4% | |
| 45–54 | 14 | 125% | 92 | 16.6% | |
| 55–64 | 13 | 11.6% | 130 | 235% | |
| 65–74 | 15 | 13.4% | 117 | 21.1% | |
| >75 | 65 | 58.0% | 140 | 253% | <.0001 |
| Socioeconomic status | |||||
| Lowest SES | 10 | 8.9% | 24 | 43% | |
| Lower-middle SES | 19 | 17.0% | 79 | 143% | |
| Middle SES | 17 | 15.2% | 97 | 175% | |
| Higher-middle SES | 32 | 28.6% | 129 | 233% | |
| Highest SES | 25 | 223% | 194 | 35.0% | |
| Missing | 9 | 8.0% | 31 | 5.6% | .0479 |
| Histology | |||||
| Malignant melanoma, NOS | 67 | 59.8% | 314 | 56.7% | |
| Nodular melanoma | 23 | 20.5% | 54 | 9.7% | |
| Lentigo maligna melanoma | 5 | 4.5% | 19 | 3.4% | |
| Superficial spreading melanoma | 15 | 13.4% | 165 | 29.8% | |
| Acral lentiginous melanoma | 2 | 1.8% | 2 | 0.4% | .0002 |
| Year of diagnosis* | |||||
| 2004–2006 | 56 | 50.0% | 276 | 49.8% | |
| 2007–2009 | 56 | 50.0% | 278 | 50.2% | .9722 |
| Lymph node biopsy | |||||
| No | 87 | 77.7% | 369 | 66.6% | |
| Yes | 24 | 21.4% | 185 | 33.4% | |
| Unknown | 1 | 0.9% | 0 | 0.0% | <.0001 |
| Chemotherapy | |||||
| No | 104 | 92.9% | 552 | 99.6% | |
| Yes | 8 | 7.1% | 1 | 0.2% | |
| Unknown | 0 | 0.0% | 1 | 0.2% | <.0001 |
| Immunotherapy | |||||
| No | 105 | 93.8% | 545 | 98.4% | |
| Yes | 6 | 5.4% | 7 | 13% | |
| Unknown | 1 | 0.9% | 2 | 0.4% | .0124 |
NOS, Not otherwise specified; SES, socioeconomic status.
*
Limited to diagnosis between 2004 and 2009 to account for difference in amount of follow-up time available.